California Transcatheter Aortic Valve Replacement (TAVR) Outcomes Report

The number of TAVR procedures have sharply increased nationwide and in California. This is the second California report for TAVR outcomes, and one of the earliest state-level reports in the country. It includes 85 state-licensed hospitals submitting TAVR data for 2023. The statewide in-hospital/30-day observed mortality rate was 2.00 percent.

Assembly Bill 133 (Chapter 143, Statutes of 2021) included revisions to existing law that allows the Department of Health Care Access and Information (HCAI) to expand cardiovascular outcomes reporting. In 2021, the HCAI Clinical Advisory Panel recommended the department proceed with hospital-level TAVR outcomes reporting. HCAI is required to use data collected by the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC)-National Cardiovascular Data Registry (NCDR) from licensed hospitals to create annual reports of performance ratings.

The information in this report provides hospitals with performance measures they can use in their review of internal processes of care and quality improvement activities, helps payers and employers spend their healthcare dollars more wisely, and helps consumers make better informed healthcare decisions.

Three hospitals: AHMC Anaheim Regional Medical Center, Los Angeles County Harbor – UCLA Medical Center, and Los Angeles General Medical Center, are non-compliant with the California Code of Regulations as they failed to submit data or complete the data release consent form to the NCDR STS/ACC TVT Registry^TM for 2023.